PRGOPerrigo Company plc

$1B

Q1 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1.0B-3.5% YoY

Gross Profit

$392M37.6% margin

Operating Income

$47M4.5% margin

Net Income

-$6M-0.6% margin

EPS (Diluted)

$-0.05

QoQ Revenue Growth

-8.3%

Cash Flow

Operating Cash Flow

-$65M

Free Cash Flow

-$90M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$9.8B

Total Liabilities

$5.4B

Stockholders' Equity

$4.4B

Cash & Equivalents

$410M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1.0B	$1.1B	-3.5%
Gross Profit	$392M	$358M	+9.7%
Operating Income	$47M	-$55M	+185.0%
Net Income	-$6M	$2M	-420.0%

Revenue Segments

Consumer Self-Care Americas

$621M59%

Consumer Self-Care International

$423M41%

Geographic Segments

UNITED STATES

$609M58%

Europe

$412M39%

Other Geographical Areas

$22M2%

IRELAND

$11M1%

PRGO Q1 2025 Earnings — Perrigo Company plc Revenue & Financial Results | Market Cap Arena